CTXR Citius Pharmaceuticals, Inc.

BEARISH Impact: 6/10 EFFECT
Horizon days Filed Jun 3, 2026 Processed 2d 9h ago SEC 9999999995-26-001857
IPO/offering going effective

Price Chart

Loading chart...

Executive Summary

The SEC declared effective Citius Pharmaceuticals' S-3 shelf registration (File No. 333-296195) on June 2, 2026. This enables the resale of 5,431,473 shares underlying warrants issued in the April 2026 registered direct offering, creating immediate overhang of ~20% of shares outstanding. The company receives no proceeds from resales, though warrant cash exercise could yield up to $4.8M.

Actionable Insight

The shelf effectiveness enables immediate warrant-share resales, likely pressuring CTXR's stock price given the ~20% overhang and distressed financials (going-concern, $4.6M cash). Monitor for selling volume spikes and any Nasdaq delisting update. The $4.8M potential cash exercise is insufficient to address the cash burn.

Key Facts

  • Effectiveness date: June 2, 2026 for S-3 shelf registration (File No. 333-296195)
  • Registration covers 5,431,473 shares of common stock for resale by selling stockholders
  • Shares are underlying warrants issued in the April 2026 registered direct offering
  • Company will not receive any proceeds from resales; potential $4.8M if all warrants exercised for cash
  • Overhang equivalent to ~20% of current shares outstanding, led by Armistice Capital
  • Filed 12 days after the S-3 registration statement (May 22, 2026)
  • Company faces going-concern risk, Nasdaq bid price non-compliance, and depleted cash runway of $4.6M

Financial Impact

Overhang of ~20% of shares outstanding; potential $4.8M cash inflow if all warrants exercised, but no proceeds from resales

dilutioncash runwayshare price

Risk Factors

  • Immediate selling pressure from warrant holders (Armistice Capital) into thin liquidity
  • Nasdaq delisting if bid price remains below $1.00
  • Going-concern risk with only $4.6M cash runway
  • Dilution overhang may deter new investors

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (8 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001857
Document: 9999999995-26-001857-index.html9999999995-26-001857
Document: 9999999995-26-001857.txt9999999995-26-001857
6 reports for CTXR
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for CTXR — sortable, filterable
Type Now
Jun 3, 2026
2d ago
EFFECT
BEARISH ★ 6/10
awaiting T+20
Jun 1, 2026
3d ago
8-K
NEUTRAL ★ 4/10
awaiting T+20
May 22, 2026
13d ago
S-3
BEARISH ★ 6/10
awaiting T+20
May 15, 2026
20d ago
8-K
BEARISH ★ 6/10
awaiting T+20
Apr 24, 2026
5w ago
8-K
BEARISH ★ 6/10
$0.6910 $0.6970▼ −0.87%▲ +4.09%$0.5638 (+18.41%)
Apr 24, 2026
6w ago
424B5
BEARISH ★ 6/10
$0.7700 $0.6730▲ +12.60%▲ +16.62%$0.5638 (+26.78%)
Showing 6 of 6

US Market Status

Market Open — Closes in 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access